In 2021, the company acquired GW Pharmaceuticals for $7.2bn, gaining the seizure medication Epidiolex (cannabidiol). In February 2024, it licensed a KRAS inhibitor programme from UK-based Redx ...

Jazz Pharma has agreed a $7.2 billion deal to by GW Pharmaceuticals and its pioneering cannabis-derived medicines, headed by childhood epilepsy drug Epidiolex. Nasdaq-listed GW is in line for $220 ...

Merely a minute into his prepared remarks during Jazz Pharmaceuticals’ fourth-quarter ... was the centerpiece of its $7.2 billion buyout of GW Pharmaceuticals in 2021. As one analyst noted ...

GW Pharmaceuticals' Epidyolex has been approved in the EU for a third epilepsy indication, giving a boost for the company ahead of its $7.2 billion takeover by Jazz Pharma.

“It’s a huge breakthrough for the concept of cannabinoids as medicines,” says Justin Gover, CEO of manufacturer GW Pharmaceuticals. Next, the company is exploring how effective CBD and other ...

Jazz Pharmaceuticals JAZZ has been analyzed by 12 analysts in the last three months, revealing a diverse range of perspectives from bullish to bearish. The following table encapsulates their recent ...

Jazz Pharmaceuticals, a Zacks Rank #1 (Strong Buy), is a specialty biopharmaceutical company that identifies, develops, and ...

Assess today's live GW Pharmaceuticals PLC (GWPRF) share price, performance and insights using our live OTC Markets: GWPRF stock exchange data. Analyse the historical data and GW Pharmaceuticals PLC ...

GW Pharmaceuticals is a cutting-edge UK-based biopharmaceutical company that over the last 20 years has established a world-leading position in cannabinoid science and the development of ...